RT Journal Article
SR Electronic
T1 mRNA-based COVID-19 booster vaccination is highly effective and cost-effective in Australia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.08.22274797
DO 10.1101/2022.05.08.22274797
A1 Li, Rui
A1 Liu, Hanting
A1 Fairley, Christopher K
A1 Ong, Jason J
A1 Guo, Yuming
A1 Zou, Zhuoru
A1 Xie, Li
A1 Zhuang, Guihua
A1 Li, Yan
A1 Shen, Mingwang
A1 Zhang, Lei
YR 2022
UL http://medrxiv.org/content/early/2022/05/10/2022.05.08.22274797.abstract
AB Background Australia implemented an mRNA-based booster vaccination strategy against the COVID-19 Omicron variant in November 2021. We aimed to evaluate the effectiveness and cost-effectiveness of the booster strategy over 180 days.Methods We developed a decision-analytic Markov model of COVID-19 to evaluate the cost-effectiveness of a booster strategy (administered 3 months after 2nd dose) in those aged ≥16 years in Australia from a healthcare system perspective. The willingness-to-pay threshold was chosen as A$ 50,000.Findings Compared with 2-doses of COVID-19 vaccines without a booster, Australia’s booster strategy would incur an additional cost of A$0.88 billion but save A$1.28 billion in direct medical cost and gain 670 quality-adjusted life years (QALYs) in 180 days of its implementation. This suggested the booster strategy is cost-saving, corresponding to a benefit-cost ratio of 1.45 and a net monetary benefit of A$0.43 billion. The strategy would prevent 1.32 million new infections, 65,170 hospitalisations, 6,927 ICU admissions and 1,348 deaths from COVID-19 in 180 days. Further, a universal booster strategy of having all individuals vaccinated with the booster shot immediately once their eligibility is met would have resulted in a gain of 1,599 QALYs, a net monetary benefit of A$1.46 billion and a benefit-cost ratio of 1.95 in 180 days.Interpretation The COVID-19 booster strategy implemented in Australia is likely to be effective and cost-effective for the Omicron epidemic. Universal booster vaccination would have further improved its effectiveness and cost-effectiveness.Funding National Natural Science Foundation of China. Bill and Melinda Gates FoundationCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThe work is supported by the Bill & Melinda Gates Foundation. LZ is supported by the National Natural Science Foundation of China (Grant number: 81950410639); Outstanding Young Scholars Funding (Grant number: 3111500001); Xi'an Jiaotong University Basic Research and Profession Grant (Grant number: xtr022019003 and xzy032020032) and Xi'an Jiaotong University Young Talent Support Grant (Grant number: YX6J004). MS was supported by the National Natural Science Foundation of China (Grant number: 12171387, 11801435), China Postdoctoral Science Foundation (Grant number: 2018M631134, 2020T130095ZX); Young Talent Support Program of Shaanxi University Association for Science and Technology (Grant number: 20210307).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript